Article

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.
Archives of general psychiatry (Impact Factor: 12.26). 02/2010; 67(2):146-54. DOI: 10.1001/archgenpsychiatry.2009.192
Source: PubMed

ABSTRACT The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation.
To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis.
Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007.
Psychosis detection unit of a large public hospital in Vienna, Austria.
Eighty-one individuals at ultra-high risk of psychotic disorder.
A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months.
The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition.
Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups.
Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.

0 Bookmarks
 · 
156 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cognitive deficits are a distinct feature among people at ultra-high risk (UHR) for psychosis and pose a barrier to functional recovery. Insufficient evidence exists on how to ameliorate these cognitive deficits in patients at UHR for psychosis and hence improve daily living and quality of life. The aim of the trial is to investigate whether cognitive remediation can improve cognitive and psychosocial function in patients at UHR for psychosis.Methods The FOCUS trial (Function and Overall Cognition in Ultra-high risk States) is a randomised, parallel group, observer-blinded clinical trial enrolling 126 patients meeting the standardised criteria of being at UHR for psychosis. Patients are recruited from psychiatric in- and outpatient facilities in the Copenhagen catchment area. Patients are randomised to one of the two treatment arms: cognitive remediation plus standard treatment versus standard treatment. The cognitive remediation consists of 24 weekly group-based and manualised sessions targeting neurocognition and social cognition. In addition to the group sessions, the patients will be offered 12 individual sessions aiming at maximising the transfer of the effects of the cognitive training to their everyday lives. Follow-up assessments will be conducted at 6 and 12 months after randomisation. The primary outcome is the composite score on the Brief Assessment of Cognition in Schizophrenia at cessation of treatment after 6 months. Secondary outcomes are social and daily functioning, psychosis-like symptoms, negative symptomatology, and depressive symptomatology as measured with the Personal and Social Performance Scale, Brief Psychiatric Rating Scale-Expanded Version, Scale for the Assessment of Negative Symptoms, and the Montgomery-Åsberg Depression Rating Scale.DiscussionThis is the first trial to evaluate the effects of neurocognitive and social cognitive remediation in UHR patients. The FOCUS trial results will provide evidence on the effect of targeted and comprehensive cognitive rehabilitation on cognition, daily living, and symptomatology as well as long-term outcome in preventing transition to psychosis in UHR patients.Trial registrationClinicalTrials.gov NCT 02098408. Date of registration 18 March 2014.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We thank the commentators for an extraordinarily diverse and constructive set of comments. Nearly all applaud our goal of sketching a unified science of change, even while raising substantive points that we look forward to addressing in our reply, which we group into the following categories: (1) What counts as evolutionary; (2) Ethical considerations; (3) Complexity; (4) Symbotypes, culture, and the future; (5) What intentional cultural change might look like; (6) An evolving science of cultural change; and (7) Who decides? We thank the commentators for an extraordinarily diverse and constructive set of comments. Nearly all applaud our goal of sketching a unified science of change, even while raising substantive points that we look forward to addressing in our reply.
    Behavioral and Brain Sciences 08/2014; 37(04):438-460. DOI:10.1017/S0140525X14000016 · 14.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Un nuevo enfoque para comprender los trastornos mentales graves, como la esquizofrenia, consiste en adoptar un modelo de estadios clínicos. Un modelo de este tipo define el grado de la enfermedad, de tal manera que los fenómenos más tempranos y más leves se diferencian de las manifestaciones más tardías y que causan un mayor deterioro. Concretamente, un modelo de estadios clínicos hace tres predicciones clave. En primer lugar, los parámetros patológicos deben ser más anormales en los estadios más graves. En segundo lugar, los pacientes que presentan una progresión del estadio deben mostrar un cambio en esos mismos parámetros patológicos. Por último, en los estadios más tempranos el tratamiento debe ser más eficaz, así como más benigno. En este artículo revisamos la evidencia existente respecto a estas tres predicciones en los estudios de trastornos psicóticos, centrándonos en los datos de neuroimagen. En los tres casos, el conjunto de la evidencia respalda las predicciones del modelo de estadios. Sin embargo, existen diversas explicaciones alternativas para estas observaciones, entre ellas los efectos de la medicación y la heterogeneidad de los síntomas.
    07/2011; 18(3):117-123. DOI:10.1016/j.psiq.2011.10.003

Full-text (2 Sources)

Download
53 Downloads
Available from
May 29, 2014